Skip to main content
OpenTrials
Completed

NCT Number: NCT06411080

UltraSound Evaluation of Fluid tOleRanCE for Acute Kidney Injury

Fluid expansion with isotonic crystalloids is a first-line intervention in the treatment of patients with acute kidney injury (AKI). While it is generally accepted that the timely correction of kidney hypoperfusion will minimize the extent of injury as well as potentially facilitate recovery, there are potential harms involved in indiscriminate administration of intravenous fluids. Although anticipating fluid tolerance is part of the clinical evaluation of a patient for whom intravenous fluid therapy is considered, it has been suggested that using Point-Of-Care ultrasound (POCUS) may enable the early identification of patients with a high-risk of congestive complications and guide clinical decisions with greater precision[1]. However, it has not been shown that providing this information in the context of AKI result in a change in management or a prevention of complications.

This single-center pilot randomized controlled trial aim to determine the feasibility of comparing a management including a POCUS evaluation of fluid tolerance to usual care in non-critically ill patients with AKI. In the intervention group, a POCUS evaluation will be performed and interpreted by experienced staff producing a report that will be presented to the attending care team. This assessment will be repeated 48-72 hours later. The primary aim of the study will be to establish the feasibility of this intervention. Secondary objectives will include determining the difference between the intervention arm and the control arm in relationship with fluid administration, diuretic use, evolution of kidney function, and intensification of care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, H2X 3H8, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥ 18 year-old
  • Admitted to the hospital
  • Acute kidney injury defined by the KDIGO criteria[48]
  • Fluid expansion is considered by attending nephrologist or already ongoing

Exclusion criteria

  • Admitted to the intensive care unit
  • Known stage 5 chronic kidney disease according to the KDIGO classification receiving renal replacement therapy or not.
  • Renal replacement therapy for AKI has been initiated or is planned within 24 hours

Treatment and study plan

Ultrasound evaluation of fluid tolerance

Diagnostic Test

Lung ultrasound for the assessment of B-line artifact and pleural effusion combined with abdominal ultrasound for VExUS assessment. The imaging study will be reviewed by an expert for will generate a report with interpretation regarding the risk of fluid administration. The assessment will be performed at baseline and after 48 hours after randomization.

Primary outcomes

  1. Protocol adherence

    Time frame: 30 days

    : Ultrasound assessments were performed as planned and the reports were generated and transmitted to the attending care team in the prespecified periods.

Secondary outcomes

  1. Cumulative intravenous fluid

    Time frame: 5 days

    Amount of fluid in mL received

  2. Diuretic use

    Time frame: 5 days

    defined as the use of loop diuretics

  3. Kinetic estimated glomerular filtration rate (KeGFR)

    Time frame: 5 days

    Kinetic estimated glomerular filtration rate (KeGFR) will be derived from serial measurements in serum creatinine

  4. Progression to a higher stage of AKI

    Time frame: 5 days

    Progression to a higher stage of AKI will be defined as any increase in the KDIGO staging criteria of increase in creatinine:

    Operational definition: Increase in at least one level compared to baseline AKI staging during the first 5 days:

    Stage 1: Increase in serum creatinine by ≥26.5 µmol/L within 48 hours or increase to 1.5-1.9 times baseline within the last 7 days.

    Stage 2: Increase in serum creatinine to 2.0-2.9 times baseline. Stage 3: Increase in serum creatinine to ≥3.0 times baseline or increase to ≥354 µmol/L, Stage 3D: Initiation of renal replacement therapy.

  5. Death or escalation of care

    Time frame: 10 days

    composite endpoint defined as the occurrence of at least one of the following events occurring within 10 days after randomization: death from any cause, intervention of the rapid response team, admission to the intensive care unit, initiation of non-invasive positive pressure ventilation, initiation of renal replacement therapy. (Binary - Yes/no)

Other outcomes

  1. Kidney and liver stiffness

    Time frame: 5 days

    median values of shear-wave propagation speed in m/sec obtained by shear-wave elastography assessment of the respective organ parenchyma.

  2. The perceived usefulness of the ultrasound report

    Time frame: 5 days

    be reported on a sliding scale from 0 to 5. A score of 0 will mean that the information is considered useless while a score of 5 will mean that the information provided had a critical impact of clinical management. (Continuous - points)

Sponsors and collaborators

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Other

Registry information

Official study title

UltraSound Evaluation of Fluid tOleRanCE for Acute Kidney Injury: A Pilot Randomized Controlled Trial

Acronym: USE-the-FORCE

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 13, 2024
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.